Firms team up to develop cancer drugs in potential $540M deal

08/6/2013 | Reuters · Genetic Engineering & Biotechnology News

Bayer HealthCare and Compugen signed a preclinical research agreement centered on antibody-based cancer immunotherapies. Bayer will get the rights to further develop and market the drugs arising from the collaboration. The deal entitles Compugen to $10 million upfront and as much as $530 million in milestone fees plus sales royalties.

View Full Article in:

Reuters · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA